<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306397</url>
  </required_header>
  <id_info>
    <org_study_id>CERL-080-CH02</org_study_id>
    <secondary_id>2004DR3379</secondary_id>
    <nct_id>NCT00306397</nct_id>
  </id_info>
  <brief_title>Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients</brief_title>
  <official_title>Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate, whether a steroid free immunosuppressive&#xD;
      treatment is a valuable alternative in the treatment of de novo kidney transplant recipients&#xD;
      and if it is possible to withdraw calcineurin inhibitors after 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol synopsis Title An open, single centre, pilot study to investigate a steroid free&#xD;
      immunosuppressive regimen for de novo renal transplant recipients followed by a two arm&#xD;
      randomization to a calcineurin inhibitor containing and a calcineurin inhibitor free&#xD;
      maintenance immunosuppression after three months. Study code Sterfree pilot study Project&#xD;
      phase An open, single centre, one arm study followed by a 1:1 randomized, parallel group,&#xD;
      comparative study after three months. Study objectives To obtain preliminary information on&#xD;
      the efficacy and safety of a rapamycin / sodium-mycophenolate (Myfortic) / tacrolimus regimen&#xD;
      in the absence of steroids for the prevention of acute rejection following renal&#xD;
      transplantation. To compare a low dose tacrolimus / rapamycin / sodium-mycophenolate&#xD;
      (Myfortic) regimen to a rapamycin / sodium-mycophenolate regimen in patients without evidence&#xD;
      of acute rejection after three months.&#xD;
&#xD;
      Efficacy:&#xD;
&#xD;
      Primary endpoint&#xD;
&#xD;
        -  Plasma creatinine (and creatinine clearance (Cockcroft)) Secondary endpoints&#xD;
&#xD;
        -  Incidence of first acute rejections and total number of acute rejections&#xD;
&#xD;
        -  Total number of anti-rejection treatments&#xD;
&#xD;
        -  Patients successfully withdrawn from calcineurin inhibitor at three months&#xD;
&#xD;
        -  Graft survival&#xD;
&#xD;
        -  Patient survival&#xD;
&#xD;
      Safety:&#xD;
&#xD;
        -  Graft survival&#xD;
&#xD;
        -  Patient survival&#xD;
&#xD;
        -  Protocol biopsies at 3 months( range: day 75 to 105) and 6 months (range day 165 to 195)&#xD;
           sub clinical rejection&#xD;
&#xD;
        -  Incidence of first acute biopsy proven rejection and total number of acute rejection&#xD;
           episodes&#xD;
&#xD;
        -  Total number of anti-rejection treatments&#xD;
&#xD;
        -  Patients switched from assigned therapy due to rejection or side effects&#xD;
&#xD;
        -  Patients needing steroids because of rejection&#xD;
&#xD;
        -  Incidence of selected adverse events: tubulointerstitial nephrotoxicity (TOR inhibitor),&#xD;
           leucopenia, thrombocytopenia, elevated fasting blood glucose, dyslipidemia, ,&#xD;
           electrolyte disturbances, de novo insulin dependency, gastrointestinal disorders (non&#xD;
           infectious), neurotoxicity.&#xD;
&#xD;
        -  Patients withdrawn due to adverse events&#xD;
&#xD;
      Long term patient follow up Patients will be followed up for graft and patient survival at&#xD;
      12, 24, and 36 months post-transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allograft function</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients successfully withdrawn from calcineurin inhibitor after three months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapamycin - MMF after 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose tacrolimus - MMF - Rapamycin after 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Sirolimus</other_name>
    <other_name>Rapammune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients with end stage kidney disease suitable for primary renal&#xD;
             transplantation or retransplantation&#xD;
&#xD;
          -  patients receiving a graft from a living related, living unrelated or brain-death&#xD;
             donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a low or high immunological risk constellation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juerg U Steiger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Clinic for Transplantation Immunology and Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Clinic for Transplantation Immunology and Nephrology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2006</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steiger Juerg / Professor</name_title>
    <organization>University Hospital Basel, Clinic for transplantation immunology and nephrology</organization>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Steroid free</keyword>
  <keyword>Calcineurin inhibitor free</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Sirolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

